-
1
-
-
0014167005
-
The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis
-
Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 1967; 126: 989-1004
-
(1967)
J Exp Med
, vol.126
, pp. 989-1004
-
-
Lerner, R.A.1
Glassock, R.J.2
Dixon, F.J.3
-
2
-
-
33645914468
-
Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: A janus-faced antigen
-
Wang XP, Fogo AB, Colon S et al. Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol 2005; 16: 3563-3571
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 3563-3571
-
-
Wang, X.P.1
Fogo, A.B.2
Colon, S.3
-
3
-
-
0035811228
-
Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression
-
Levy JB, Turner AN, Rees AJ et al. Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134: 1033-1042
-
(2001)
Ann Intern Med
, vol.134
, pp. 1033-1042
-
-
Levy, J.B.1
Turner, A.N.2
Rees, A.J.3
-
4
-
-
0016842012
-
Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis
-
Lockwood CM, Boulton-Jones JM, Lowenthal RM et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975; 2: 252-254
-
(1975)
Br Med J
, vol.2
, pp. 252-254
-
-
Lockwood, C.M.1
Boulton-Jones, J.M.2
Lowenthal, R.M.3
-
5
-
-
0035122440
-
Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti CD20 monoclonal antibody
-
Gonzales-Stawinski GV, Yu PB, Parker W et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti CD20 monoclonal antibody. Clin Immunol 2001; 98: 175-179
-
(2001)
Clin Immunol
, vol.98
, pp. 175-179
-
-
Gonzales-Stawinski, G.V.1
Yu, P.B.2
Parker, W.3
-
6
-
-
0036785195
-
Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
-
Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61: 922-924
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 922-924
-
-
Arzoo, K.1
Sadeghi, S.2
Liebman, H.A.3
-
7
-
-
63349100547
-
Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy
-
Sauter M, Schmid H, Anders HJ et al. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy. Clin Transplant 2009; 23: 132-136
-
(2009)
Clin Transplant
, vol.23
, pp. 132-136
-
-
Sauter, M.1
Schmid, H.2
Anders, H.J.3
-
8
-
-
0036682502
-
Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody
-
Matteucci P, Magni M, Di Nicola M et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 100: 1104-1115
-
(2002)
Blood
, vol.100
, pp. 1104-1115
-
-
Matteucci, P.1
Magni, M.2
Di Nicola, M.3
|